MoneyWorks4Me

Clarification sought from Sanofi India

29 Mar 2017 Evaluate

The Exchange has sought clarification from Sanofi India on March 29, 2017, with reference to the news flashed on www.reuters.com dated March 29, 2017 quoting ‘FDA Approves Regeneron, Sanofi $37,000 per year eczema drug’.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..